Exelixis (EXEL) is a publicly traded Healthcare sector company. As of November 17, 2026, EXEL trades at $68.50 with a market cap of $16.37B and a P/E ratio of 32.55. EXEL moved +2.09% today. Year to date, EXEL is +61.56%; over the trailing twelve months it is +61.48%. Its 52-week range spans $32.38 to $73.69. Analyst consensus is neutral with an average price target of $59.82. Rallies surfaces EXEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Exelixis (EXEL) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. EXEL moved +2.09% today. Analyst consensus is neutral.
| Metric | Value |
|---|---|
| Price | $68.50 |
| Market Cap | $16.37B |
| P/E Ratio | 32.55 |
| EPS | $1.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $73.69 |
| 52-Week Low | $32.38 |
| Volume | 1.92M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.17B |
| Net Income | $521.27M |
| Gross Margin | 96.49% |
13 analysts cover EXEL: 0 strong buy, 4 buy, 8 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $59.82.